Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial

Yukinori Harada¹, Roisin Colleran¹, Sebastian Kufner¹, Daniele Giacoppo¹, Tobias Rheude¹, Jonathan Michel¹, Salvatore Cassese¹, Tareq Ibrahim², Karl-Ludwig Laugwitz², Adnan Kastrati¹, Robert A. Byrne¹* and for the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) Investigators

Abstract

Background: Improved outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention remain an unmet clinical need. We assessed the long-term efficacy and safety of novel polymer-free sirolimus- and probucol-eluting stent in diabetic patients enrolled in intracoronary stenting and angiographic results: test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents 5 trial.

Methods: In a pre-specified subgroup analysis, outcomes of diabetic patients treated with a sirolimus- and probucol-eluting stent or a second-generation zotarolimus-eluting stent were compared. The primary endpoint was a device-oriented composite outcome comprising cardiac death, target vessel-related myocardial infarction (MI), or target lesion revascularization (TLR) at 5-year follow-up. Event-free survival was assessed using the Kaplan–Meier method. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated from univariate Cox proportional hazards models.

Results: A total of 870 patients with diabetes mellitus were treated with either a sirolimus- and probucol-eluting stent (n = 575) or a second-generation zotarolimus-eluting stent (n = 295). At 5 years, the rate of device-oriented composite endpoint was comparable between the sirolimus- and probucol-eluting stent and the second-generation zotarolimus-eluting stent (32.9 versus 33.4%, HR 0.88, 95% CI 0.76–1.26). No significant differences were observed between the sirolimus- and probucol-eluting stent and the second-generation zotarolimus-eluting stent groups in the incidence of cardiac death (15.6 versus 16.7%, HR 0.92, 95% CI 0.63–1.32), target-vessel MI (4.6 versus 6.6%, HR 0.73, 95% CI 0.40–1.34), and TLR (18.6 versus 18.8%, HR 1.00, 95% CI 0.72–1.41). The rate of definite or probable stent thrombosis was low and similar in both groups (2.5 versus 2.6%, HR 1.02, 95% CI, 0.41–2.52).
**Conclusions:** In patients with diabetes the long-term efficacy and safety of a polymer-free sirolimus- and probucol-eluting stent were comparable to a second-generation durable polymer zotarolimus-eluting stent.

**Trial registration** ClinicalTrials.gov NCT00598533. Registered 10 January 2008

**Keywords:** Diabetes, Drug-Eluting Stent, Probucol, Sirolimus, Zotarolimus

**Background**

High rates of adverse events remain a cause of concern in patients with diabetes mellitus after percutaneous coronary intervention for obstructive coronary artery disease [1, 2]. Second-generation durable polymer drug-eluting stents (DES), including a durable polymer zotarolimus-eluting stent, have demonstrated good efficacy in the treatment of coronary artery disease in diabetic patients [3, 4]. However, persistent inflammatory response to durable polymer coatings of DES is recognized as a leading cause of delayed arterial healing and one of the key factors underlying late stent failure in patients who undergo DES implantation [5, 6]. Indeed, this issue is of particular relevance in the setting of diabetic patients with high atherothrombotic risk [2, 7].

Against this background polymer-free DES showed non-inferior short-term angiographic outcomes in comparison with a durable polymer-based everolimus-eluting stent in the setting of diabetic patients [8]. However, the efficacy and safety of polymer-free DES compared with durable polymer-based second-generation DES in diabetic patients are poorly defined and very long-term outcomes are underexplored with data almost exclusively deriving from comparison with outdated first-generation polymer-based DES [9].

The intracoronary stenting and angiographic results: test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents (ISAR-TEST) 5 trial demonstrated the non-inferiority of a polymer-free dual drug sirolimus- and probucol-eluting stent in comparison with a durable polymer DES for the clinical endpoints of interest at 1 year follow up [10]. In addition, long-term follow-up of patients enrolled in this trial showed consistent results over time with comparable safety and efficacy between the two devices at 5 years follow up [11]. The aim of our study was to assess 5-year clinical outcomes of patients with diabetes mellitus who underwent angioplasty with a polymer-free dual drug sirolimus- and probucol-eluting stent or a second-generation durable polymer zotarolimus-eluting stent implantation enrolled in the ISAR-TEST 5 trial.

**Methods**

**Study population and study protocol**

The primary analysis of the ISAR-TEST 5 clinical trial was previously reported [10]. Patients with diabetes mellitus represented a pre-specified subgroup of interest according to the trial protocol. In brief, the ISAR-TEST 5 trial was a randomized, non-inferiority trial conducted between February 2008 and August 2009, in which 3002 patients with ischemic symptoms or evidence of inducible or spontaneous myocardial ischemia and one or more ≥50 % de novo stenosis located in native coronary vessels were assigned in a 2:1 treatment allocation to receive either a polymer-free dual drug sirolimus- and probucol-eluting stent (backbone Yukon stent, Translumina, Hechingen, Germany; stent currently commercially available as Coroflex Isar stent, B. Braun Melsungen AG, Melsungen, Germany) or a second-generation durable polymer zotarolimus-eluting stent (Endeavor Resolute, Medtronic Vascular, Santa Rosa, CA, USA). Minimal exclusion criteria were applied, with exclusion only of patients presenting left main stenosis, cardiogenic shock, malignancies, life expectancy <12 months, known allergies to study medication and pregnancy. Randomization sequence was computer generated with allocation concealment by means of sealed opaque envelopes. Randomization was done immediately after crossing the lesion with the guide-wire. In case of multiple lesions requiring intervention, the same assigned stent was to be implanted in all lesions.

The trial was registered at http://www.clinicaltrials.gov. (trial identifier: NCT00598533). The study was conducted in accordance with the provisions of the Declaration of Helsinki and with the International Conference on Harmonization Good Clinical Practices. The trial protocol was approved by the institutional ethics committee of the participating centers and all included patients provided specific written informed consent.

Patients were systematically evaluated at 1, 12, 24 and 60 months by telephone call or office visit. All events were adjudicated and classified by an event adjudication committee unaware of treatment allocation. According to the trial protocol, follow-up coronary angiography was scheduled at 6–8 months and both off-line quantitative coronary angiography and qualitative assessment were performed in an independent core laboratory (ISARESEARCHCenter, Munich, Germany).

**Study devices and anti-thrombotic medications**

The polymer-free stent platform consists of a pre-mounted, thin strut (87 μm), sand-blasted, 316L stainless...
steel microporous stent coated with a matrix of sirolimus (0.7 %) and probucol (0.7 %) [10, 12, 13]. The distribution concentration of sirolimus is 120 mg/cm\(^2\) stent and of probucol is 100 mg/cm\(^2\). Non-clinical testing showed that no traces of sirolimus or probucol are observable beyond 6–8 weeks [13]. The second-generation durable polymer zotarolimus-eluting stent uses a bare metal cobalt-chromium platform coated with zotarolimus and the BioLinx polymer system [14].

An oral loading dose of 600-mg clopidogrel was administered to all patients at least 2 h before the intervention, regardless of whether the patient was taking clopidogrel before being admitted. During the procedure, intravenous aspirin, heparin or bivalirudin, and glycoprotein IIb/IIIa inhibitor administration was at the discretion of the operators. After the intervention, all patients, regardless of treatment allocation, were prescribed 200 mg/day aspirin indefinitely, clopidogrel 150 mg for the first 3 days or until discharge followed by 75 mg/day for at least 6 months.

**End points and definitions**

The primary endpoint of ISAR-TEST 5 was the device-oriented composite of cardiac death, target vessel-related myocardial infarction, or target lesion revascularization at 5 years (final study follow up). Secondary endpoints were as follows: cardiac death, all-cause death, target vessel myocardial infarction, any myocardial infarction, target lesion revascularization, any revascularization, target vessel revascularization and the incidence of definite/probable stent thrombosis (by Academic Research Consortium definition) in the diabetic subgroup at 5 years. Detailed definitions of endpoints have been previously reported [10].

**Statistical analysis**

The analysis of primary and secondary endpoints was planned to be performed on an intention-to-treat basis. Continuous data are presented as mean (standard deviation) or median (25th–75th percentiles) according to data distribution testing by the Kolmogorov–Smirnov test. Categorical data are presented as counts and proportions (%). Differences of clinical characteristics between groups were inspected using the Student’s t or Wilcoxon rank sum test for continuous variables and the Chi squared or Fisher’s exact test for categorical variables (patient-level). Angiographic differences between groups were compared using generalized estimating equations for non-normally distributed data [15], in order to address intra-patient correlation in patients who underwent multi-lesion intervention. Event-free survival was assessed using the Kaplan–Meier method and differences were quantified by the log-rank test. Hazard ratios (HR) with accompanying 95 % confidence intervals (CI) were estimated from univariate Cox proportional hazards models. The proportional hazards assumption checked by the method of Grambsch and Therneau [16] was fulfilled in all cases in which we used Cox proportional hazards models. Statistical software S-PLUS, version 4.5 (S-PLUS, Insightful Corp, Seattle, Wa, USA) was used for analyses.

**Results**

**Patient, lesion, and procedural characteristics and angiographic outcomes**

Of a total of 3002 patients enrolled in the ISAR-TEST 5 trial, 870 patients with diabetes mellitus were identified: 575 patients were assigned to treatment with polymer-free sirolimus- and probucol-eluting stent and 295 to durable polymer zotarolimus-eluting stent (Fig. 1). The groups were well matched in terms of baseline patient and lesion characteristics (Table 1). Prevalence of patients requiring insulin treatment (P = 0.43) and oral anti-diabetic therapy only (P = 0.94) were comparable between groups. A total of 1288 coronary lesions received percutaneous coronary intervention (sirolimus- and probucol-eluting stent, n = 849; zotarolimus-eluting stent, n = 439). Prevalence of patients with multiple lesions which treated with stent implantation was comparable between groups (P = 0.61). Procedural characteristics were broadly comparable between the two groups except post-procedural minimal luminal diameter and percent diameter stenosis (Table 2).

Angiographic outcomes at 6–8 months are shown in Table 2. In-stent late lumen loss and in-segment percent diameter stenosis at angiographic follow-up were not different between the treatment groups.

---

**Fig. 1** Patient flow in this study
Table 1  Baseline clinical characteristics

| Patient-level characteristics | Sirolimus- and probucol-eluting stent (n = 575) | Zotarolimus-eluting stent (n = 295) | P value |
|--------------------------------|-----------------------------------------------|--------------------------------------|---------|
| Age (years)                    | 69 (61–76)                                   | 70 (62–76)                           | 0.40    |
| Female                         | 150 (26.1)                                   | 79 (26.8)                            | 0.83    |
| Diabetes mellitus therapy      |                                              |                                      |         |
| Insulin                        | 197 (34.0)                                   | 109 (37.0)                           | 0.43    |
| Oral antidiabetic drugs        | 289 (50.0)                                   | 149 (51.0)                           | 0.94    |
| Hypertension                   | 547 (95.1)                                   | 281 (95.3)                           | 0.94    |
| Hypercholesterolemia           | 389 (68.0)                                   | 188 (64.0)                           | 0.25    |
| Current smoker                 | 105 (18.0)                                   | 52 (18.0)                            | 0.82    |
| Prior myocardial infarction    | 177 (30.8)                                   | 85 (28.8)                            | 0.55    |
| Prior bypass surgery           | 59 (10.3)                                    | 34 (11.5)                            | 0.57    |
| Clinical presentation          |                                              |                                      | 0.46    |
| Silent ischemia                | 36 (6.3)                                     | 15 (5.1)                             |         |
| Stable angina                  | 324 (56.3)                                   | 154 (52.2)                           |         |
| Unstable angina                | 98 (17.0)                                    | 61 (20.7)                            |         |
| Non ST-segment elevation myocardial infarction | 73 (12.7)                                   | 45 (15.3)                            |         |
| ST-segment elevation myocardial infarction | 44 (7.7 %)                                  | 20 (6.8 %)                           |         |
| Multi-vessel disease           | 517 (89.9)                                   | 263 (89.2)                           | 0.73    |
| Ejection fraction (%)a         | 54 (44-60)                                   | 55 (41–61)                           | 0.56    |
| Lesion-level characteristics   |                                              |                                      |         |
| Target vessel                  |                                              |                                      | 0.11    |
| Left anterior descending       | 336 (39.6)                                   | 196 (44.6)                           |         |
| Left circumflex                | 236 (27.8)                                   | 123 (28.0)                           |         |
| Right coronary artery          | 277 (32.6)                                   | 120 (27.3)                           |         |
| Chronic total occlusion        | 56 (6.6)                                     | 22 (5.0)                             | 0.26    |
| Bifurcation                    | 200 (23.6)                                   | 112 (25.5)                           | 0.44    |
| Ostial                         | 152 (17.9)                                   | 80 (18.2)                            | 0.89    |
| Complex morphology             | 626 (74.0)                                   | 336 (77.0)                           | 0.27    |
| Lesion length (mm)             | 16.6 ± 9.5                                   | 17.9 ± 10.4                          | 0.07    |
| Reference vessel diameter (mm) | 2.75 ± 0.52                                  | 2.79 ± 0.51                          | 0.36    |
| Minimal luminal diameter (mm)  | 0.91 ± 0.50                                  | 0.92 ± 0.47                          | 0.83    |
| Percent diameter stenosis (%)  | 67 ± 16                                      | 67 ± 15                               | 0.83    |

Data shown as mean ± SD, median (25th–75th percentiles), or n (%)

* Data available for 725 patients (86.7 %)

Outcomes at 5 years

Five-year clinical outcomes are shown in Table 3. There was no significant difference in the occurrence of the primary composite endpoint at 5 years between the polymer-free sirolimus- and probucol-eluting stent and durable polymer zotarolimus-eluting stent groups (32.9 versus 33.4 % respectively, HR = 0.88, 95 % CI, 0.76–1.26; P = 0.88)(Fig. 2). In terms of the individual components of the primary endpoint, rates were similar between the two groups: the composite of cardiac death or target vessel myocardial infarction was, 19.1 versus 20.1 % respectively (HR 0.94, 95 % CI, 0.67–1.30; P = 0.70) (Fig. 3a), and target lesion revascularization was, 18.6 versus 18.8 % respectively (HR 1.00, 95 % CI, 0.72–1.41; P = 0.98) (Fig. 3b). There were also no differences of the incidences of other secondary endpoints of all-cause death, any myocardial infarction, any revascularization, and target vessel revascularization.

The rate of definite or probable stent thrombosis was low and similar in both groups (2.5 versus 2.6 % respectively, HR 1.02, 95 % CI, 0.41–2.52; P = 0.97), with only one case occurring in the durable polymer zotarolimus-eluting stent group after 12 months (Fig. 4).
Main findings in this study

In the high-risk subgroup of patients with diabetes mellitus enrolled in a large-scale randomized trial with broad inclusion criteria, the composite primary endpoint of cardiac death, myocardial infarction-related to the target vessel, or target lesion revascularization at 5-year follow-up in subjects treated with a polymer-free sirolimus- and probucol-eluting stent was non-inferior compared to that in patients treated with a second-generation durable polymer zotarolimus-eluting stent. Moreover, each of the individual cardiovascular endpoints was comparable between groups. In particular, the incidence of stent thrombosis was low and comparable in both treatment groups with few events beyond 12 months.

Table 2 Procedural characteristics and angiographic outcomes

| Lesion-level characteristics                  | Sirolimus- and probucol-eluting stent (n = 849) | Zotarolimus-eluting stent (n = 439) | P value |
|-----------------------------------------------|-------------------------------------------------|-------------------------------------|---------|
| Balloon diameter (mm)                         | 3.05 (2.59–3.47)                                | 3.02 (2.60–3.45)                    | 0.82    |
| Stented length (mm)                           | 25 (18–34)                                      | 24 (18–33)                          | 0.23    |
| **In stent analysis**                         |                                                 |                                     |         |
| Post-procedural minimal luminal diameter (mm) | 2.50 ± 0.50                                     | 2.57 ± 0.49                         | 0.045   |
| Post-procedural percent diameter stenosis (%)| 12 ± 7                                          | 11 ± 7                              | 0.03    |
| At follow-up minimal luminal diameter (mm)²  | 2.13 ± 0.73                                     | 2.20 ± 0.72                         | 0.18    |
| At follow-up percent diameter stenosis (%)²  | 24 ± 22                                         | 23 ± 21                             | 0.68    |
| Late lumen loss (mm)²                         | 0.36 ± 0.63                                     | 0.36 ± 0.59                         | 0.48    |
| **In segment analysis**                       |                                                 |                                     |         |
| Post-procedural minimal luminal diameter (mm)| 2.23 ± 0.58                                     | 2.26 ± 0.55                         | 0.33    |
| Post-procedural percent diameter stenosis (%)| 22 ± 12                                         | 22 ± 12                             | 0.83    |
| At follow-up minimal luminal diameter (mm)²  | 1.90 ± 0.70                                     | 1.98 ± 0.69                         | 0.10    |
| At follow-up percent diameter stenosis (%)²  | 33 ± 20                                         | 32 ± 19                             | 0.20    |
| Late lumen loss (mm)²                         | 0.31 ± 0.61                                     | 0.26 ± 0.57                         | 0.34    |
| Binary restenosis²                            | 107 (17.0)                                      | 57 (17.2)                           | 0.95    |

*Data shown as mean ± SD or median (25th–75th percentiles) or n (%)
* Data available for 961 lesions (74.6 %)

Table 3 Clinical results at 5 years

|                                | Sirolimus- and probucol-eluting stent (n = 575) | Zotarolimus-eluting stent (n = 295) | Hazard ratio [95 % CI] | P value |
|--------------------------------|-------------------------------------------------|-------------------------------------|------------------------|---------|
| Cardiac death, target vessel-related myocardial infarction or target lesion revascularization | 178 (32.9)                                      | 91 (33.4)                           | 0.98 [0.76–1.26]       | 0.88    |
| Cardiac death or target vessel-related myocardial infarction | 101 (19.1)                                      | 54 (20.1)                           | 0.94 [0.67–1.30]       | 0.70    |
| Cardiac death                  | 81 (15.6)                                       | 44 (16.7)                           | 0.92 [0.63–1.32]       | 0.64    |
| Target vessel-related myocardial infarction | 26 (4.6)                                        | 18 (6.6)                            | 0.73 [0.40–1.34]       | 0.31    |
| Target lesion revascularization | 100 (18.6)                                      | 50 (18.8)                           | 1.00 [0.72–1.41]       | 0.98    |
| All-cause death                | 133 (24.4)                                      | 79 (27.8)                           | 0.84 [0.63–1.11]       | 0.21    |
| Any myocardial infarction      | 37 (6.5)                                        | 21 (7.6)                            | 0.90 [0.53–1.54]       | 0.70    |
| Any revascularization          | 234 (43.4)                                      | 124 (46.9)                          | 0.92 [0.74–1.15]       | 0.48    |
| Target vessel revascularization | 144 (26.8)                                      | 70 (26.2)                           | 0.82 [0.78–1.37]       | 0.82    |
| Definite or probable stent thrombosis | 14 (2.5)                                        | 7 (2.6)                             | 1.02 [0.41–2.52]       | 0.97    |
| Definite stent thrombosis      | 7 (1.2)                                         | 4 (1.6)                             | 0.89 [0.26–3.04]       | 0.85    |
| Probable stent thrombosis      | 7 (1.2)                                         | 3 (1.0)                             | 1.19 [0.31–4.60]       | 0.80    |

*Data shown as n (%) or hazard ratio [95 % CI]
* Rates are estimated by Kaplan–Meier method; hazard ratios and p values were calculated by Cox’s proportional hazard methods
* CI confidence intervals

Discussion

Main findings in this study
Relationship between polymer coatings and adverse cardiac events
In patients with diabetes mellitus undergoing coronary stenting, the rates of adverse cardiac events such as in-stent restenosis, myocardial infarction and cardiac death remain high even after implantation of second-generation DES [1–3]. Moreover, these adverse cardiac events rates are higher in diabetic patients who require insulin treatment than in those who do not require it [17]. Indeed, higher incidences of in-stent neoatherosclerosis and very late stent thrombosis were observed in diabetic patients compared with non-diabetic patients [18, 19]. Both of the latter processes are likely related to delayed arterial healing [20, 21], which is at least in part caused by an inflammatory reaction to the polymer coatings used on DES [5, 6]. On this basis, polymer-free stent design might be an approach particularly well-suited for the treatment of coronary artery disease in diabetic patients.

Efficacy and safety of polymer-free drug-eluting stents
Prior investigation in diabetic patients showed that a polymer-free sirolimus-eluting stent had similar long-term efficacy and safety compared with a first-generation paclitaxel-eluting stent [9]. However, this data was limited by the fact that the comparator stent was an early-generation DES with only moderate antirestenotic efficacy, which has subsequently fallen out of clinical use. In addition, the study stent was coated only with sirolimus, an approach that likely does not result in adequate clinical efficacy. In our study, in a large cohort of diabetic patient we showed comparable clinical efficacy at 5 years between a polymer-free sirolimus- and probucol-eluting stent compared with a high performance second-generation durable polymer zotarolimus-eluting stent. As previously reported the improved angiographic antirestenotic efficacy with the polymer-free stent used in our study (in comparison with a similar single-drug polymer-free stent) are likely due to the incorporation of probucol in the stent coating [13, 22]. This compensates for the inherently less favorable drug-release kinetic seen with polymer-free DES. The mechanism of benefit is likely twofold: as probucol is highly lipophilic it can retard the release of sirolimus from the stent surface and improve tissue drug levels, in addition, due to the antioxidant effects of probucol it targets a separate component of the restenotic response cascade [23, 24].
Fig. 3  Time to event curve in cumulative incidences of the components of primary endpoint (a) the composite of cardiac death, target vessel-related myocardial infarction. b Target lesion revascularization. Hazard ratios and P values are derived from Cox proportional hazard methods. CI confidence interval, HR hazard ratio
Importantly, the polymer-free sirolimus- and probucol-eluting stent also demonstrated a low incidence of stent thrombosis out to 5 years. Indeed we observed no cases of stent thrombosis beyond 1 year in patients treated with the polymer-free stent in this study. On the other hand, it should be observed that no clear advantage could be seen with polymer-free stents in comparison to durable polymer stents with regard to very late stent thrombosis. Indeed this is broadly in line with results of a recent meta-analysis of both diabetic and nondiabetic patients [25], though this lack of difference must be interpreted in light of the low event rates in both groups.

With regard to angiographic antirestenotic efficacy, the late lumen loss observed in patients with diabetes in our study was 0.36 mm (in stent) both with sirolimus- and probucol-eluting and zotarolimus-eluting stents. This is somewhat higher than in other studies investigating patients with diabetes. For example in the SPIRIT V diabetic study, late loss was 0.19 mm; in the RESORVOIR study, 0.24 mm with everolimus-eluting stent [8, 26]. Although the reasons for this are unclear, this may be related to baseline patient and lesion complexity: the inclusion criteria in our study were broader and exclusion criteria were fewer. Moreover, our results may be expected to be representative of real-world practice and therefore broadly applicable to diabetic patients in a wide variety of settings.

Limitations
Our study has several limitations. First, because this is a post hoc analysis at 5 years, results must be interpreted with caution. Second, despite including 870 patients, this substudy was not powered to show a difference in the occurrence of the primary endpoint between the two groups at 5 years as well as in rarely-occurring individual endpoints such as stent thrombosis. Third, although the target lesion revascularization rates of both stents in our study were relatively high, these results were likely influenced by requirement for protocol-mandated angiographic follow-up. This is known to inflate the rate of revascularization in comparison with routine clinical practice. In fact, most cases with target lesion revascularization were observed between 6 and 8 months after index intervention. However, despite potential for greater absolute differences between stents in trials with angiographic follow-up, relative differences observed are expected to be real [27]. Fourth, although we recommended patients to continue dual antiplatelet therapy at least 12 months, data concerning the actual duration of dual anti-platelet therapy received was not captured.
Conclusions
In the setting of a large-scale randomized trial with broad inclusion criteria, cardiovascular outcomes at 5 years follow-up of diabetic patients treated with a polymer-free sirolimus- and probucol-eluting stent were non-inferior to those of patients receiving a second-generation durable polymer zotarolimus-eluting stent. Rates of stent thrombosis were comparable and satisfactory low, with few events beyond 12 months.

Abbreviations
Cl: confidence intervals; DES: drug-eluting stent; HR: hazard ratios; ISAR-TEST: intracoronary stenting and angiographic result test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents.

Authors’ contributions
YH, AK and RAB made substantial contributions to conception and design of the present analysis. All authors were involved in acquisition of data, or analysis and interpretation of data. YH, RC, DG and RAB drafted the first version of the manuscript; SK, TR, JM, SC, TI, K-KL and AK revised it critically for important intellectual content. All authors gave final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Acknowledgements
None.

Competing interests
RC reports receiving support from the Irish Board for Training in Cardiovascular Medicine sponsored by MSD. AK reports patent applications related to polymer-free sirolimus- and probucol-eluting versus zotarolimus-eluting stents.

Availability of data and materials
The datasets on which the conclusions of the manuscript are based are presen tly not deposited in a publicly-accessible repository as the ethics committee approval from the Technische Universität München (2007) did not foresee provision for this.

Ethics, consent and permissions
The trial protocol was approved by the institutional ethics committee of and appropriately investigated and resolved. All authors read and approved the final manuscript.

Funding
Funding was provided in part by the Bavarian Research Foundation (BFS-ISAR Aktenzeichen AZ: 504/02 and BFS-DES Aktenzeichen AZ: 668/05) and by the European Union FP7 (PRESTIGE 260309).

Received: 9 June 2016 Accepted: 25 July 2016 Published online: 01 September 2016

References
1. Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibshaim T, et al. Incidence and predictors of restenosis after coronary stenting in 10,004 patients with surveillance angiography. Heart. 2014;100:153–9.
2. Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J. 2011;32:2748–57.
3. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ. 2012;345:e5170.
4. Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, et al. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. JACC Cardiovasc Inter. 2014;7:471–81.
5. Finn AV, Nakazawa G, Joner M, Koldodje FD, Mont CK, Gold HK, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arteneroscler Thromb Vasc Biol. 2007;27:1500–10.
6. Joner M, Finn AV, Farb A, Mont CK, Koldodje FD, Ladic E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.
7. Mazzone T, Chait A, Pitzutzki J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371:1800–9.
8. Romaguera R, Gomez-Hospital JA, Gomez-Lara J, Brugaletta S, Pinar E, Jimenez-Quevedo P, et al. A randomized comparison of reservoir-based polymer-free amphiﬂimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus: the reservoir clinical trial. JACC Cardiovasc Inter. 2016;9:42–50.
9. Stermaier T, Heinz A, Schlama D, Kleiner Z, Danschel W, Erbs S, et al. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial). Catheter Cardiovasc Inter. 2014;83:418–24.
10. Maasberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary stenting and angiographic results: test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents (ISAR-TEST 5) trial. Circulation. 2011;124:624–32.
11. Kufner S, Sorges J, Mehlli J, Cassese S, Repp J, Wiebe J, et al. Randomized trial of polymer-free sirolimus- and probucol-eluting stents versus durable polymer zotarolimus-eluting stents: 5-Year results of the ISAR-TEST-5 trial. JACC Cardiovasc Inter. 2016;9:784–92.
12. Byrne RA, Joner M, Kastrati A, Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol. 2009;57:567–84.
13. Byrne RA, Mehlli J, Iijima R, Schulz S, Pache J, Seyfarth M, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J. 2009;30:923–31.
14. Meredith IT, Worthley S, Whithbourn R, Walters D, Popma J, Cutlip D, et al. The next-generation endeavor resolute stent: 4-month clinical and angiographic results from the endeavor resolute first-in-man trial. EuroIntervention. 2007;3:50–3.
15. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121–30.
16. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–26.
17. Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis. Cardiovasc Diabetol. 2015;14:13.
18. Schoos MM, Dangas GD, Mehran R, Kirtane AJ, Yu J, Liederbach C, et al. Impact of hemoglobin A1c levels on residual platelet reactivity and outcomes after insertion of coronary drug-eluting stents (from the ADAPT-DES Study). Am J Cardiol. 2016;117:192–200.
19. Tian F, Chen Y, Liu H, Zhang T, Guo J, Jin Q. Assessment of characteristics of neointimal hyperplasia after drug-eluting stent implantation in patients with diabetes mellitus: an optical coherence tomography analysis. Cardiology. 2014;128:34–40.
20. Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59:2515–7.
21. Otsuka F, Byrne RA, Yahagi K, Mon H, Ladich E, Fowler DR, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147–59.
22. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jasnke B, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006;113:273–9.
23. Guerra E, Byrne RA, Kastrati A. Pharmacological inhibition of coronary restenosis: systemic and local approaches. Expert Opin Pharmacother. 2014;15:2155–71.
24. Liu J, Li M, Lu H, Qiao W, Xi D, Luo T, et al. Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0124021.
25. Navarese EP, Kowalewski M, Cortese B, Kandzari D, Dias S, Wojakowski W, et al. Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. Atherosclerosis. 2014;233:224–31.
26. Grube E, Chevalier B, Guagliumi G, Smits PC, Stuteville M, Durance C, et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J. 2012;163(867–75):e861.
27. Uchida T, Popma J, Stone GW, Ellis SG, Turco MA, Ormiston JA, et al. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of ‘oculostenotic’ re-intervention in patients with intermediate lesions. JACC Cardiovasc Interv. 2010;3:403–11.